|  |  |
| --- | --- |
| **Organisation Name** | **Year-Month of Inspection** |
| Accord | Jan-20 |
| Allergan | Jan-20 |
| Eisai | Feb-20 |
| Bristol-Myers Squibb | Mar-20 |
| Ipsen Pharma | Apr-20 |
| Max Remedies | Apr-20 |
| Bausch & Lombe / PHARMASWISS ČESKÁ REPUBLIKA S.R.O. | Apr-20 |
| Otsuka | May-20 |
| Morningside | May-20 |
| Milpharm / Aurobindo | May-20 |
| Eli Lilly | Jun-20 |
| Celgene | Jul-20 |
| STADA Arzneimittel AG / Genus | Jul-20 |
| Chiesi Farmaceutici S.P.A. | Aug-20 |
| Swedish Orphan Biovitrum AB (publ) | Aug-20 |
| Bristol Laboratories | Sep-20 |
| Pierre Fabre | Sep-20 |
| Seqirus | Sep-20 |
| BioMarin Europe Ltd | Sep-20 |
| Aspar | Sep-20 |
| Gedeon Richter Plc. | Oct-20 |
| Boehringer Ingelheim International GmbH | Nov-20 |
| Vertex Pharmaceuticals (U.K.) Ltd. | Dec-20 |
| Pfizer | Dec-20 |
| AstraZeneca | Jan-21 |